CORE--CLINICAL RESEARCH AND PATIENT CARE

北方医院的临床研究和患者护理核心计划 加州综合镰刀细胞中心(NCCSCC)应用程序基于 在东湾儿童医院和奥克兰高地医院，以及 在旧金山的西湾，总医院/华盛顿大学 加利福尼亚州，旧金山。在这些项目中登记的大量患者 合作临床计划为临床提供了一个理想的资源 和建议的基础研究项目。自1978年以来，多国- 我们中心的纪律人员定期开会讨论 患者管理问题，评估正在进行的临床和基础研究 项目，并计划新的研究。这些互动的成功之处在于 反映在我们与基础和临床研究有关的出版物中 镰状细胞病(列于工作进度摘要报告)，在我们的 参与制定治疗指南的国家努力 镰状细胞病患者和我们对理解的贡献 镰状细胞临床并发症的病因和机制。这 应用描述了一些新的临床研究项目：1)抗肿瘤 镰刀剂包括羟基脲-苯丁酸钠、镁 克霉唑治疗；2)去铁酮(L1)治疗；3)中枢神经系统缺血；4) 骨髓移植在治疗镰状细胞病中的应用 血液移植与少数民族脐带血献血者的发展 程序。除了上述项目，核心将被证明是必要的 许多基础研究项目的样本。总而言之，中国的实力 临床核心在我们中心的应用将使我们能够完成 成功提出临床研究项目，参与基础研究 研究和提高对心绞痛的病因和治疗的认识 许多镰状细胞并发症。

The clinical research and patient care core programs for the Northern California Comprehensive Sickle Cell Center (NCCSCC) application are based in the East Bay at Children's Hospital and Highland Hospital Oakland, and in the West Bay at San Francisco, General Hospital/University of California, San Francisco. The large patient population enrolled in these cooperative clinical programs provides an ideal source to conduct clinical and basic research projects as proposed. Since 1978, the multi- disciplinary staff of our center has met on a regular basis to discuss patient management issues, evaluate ongoing clinical and basic research projects, and plan new research. The success of these interactions is reflected in our publications related to basic and clinical research on sickle cell disease (listed in the summary progress report), in our participation in national efforts to establish treatment guidelines for patients with sickle cell disease and in our contribution to understanding the etiology and mechanism of sickle cell clinical complications. This application describes a number of new clinical research projects: 1) anti- sickling agents including hydroxyurea-sodium phenylbutyrate, magnesium therapy, clotrimazole; 2) Deferiprone (L1) therapy; 3) CNS ischemia; 4) bone marrow transplant in the treatment of sickle cell disease; 5) core blood transplant and the development of a minority cord blood donor program. In addition the above project, the core will proved necessary samples for many basic research projects. In summary, the strength of the clinical core in our center application will enable us to complete successfully the proposed clinical research projects, participate in basic research and improve the understanding of the etiology and treatment of many sickle cell complications.